The Centers for Medicare and Medicaid Services recently announced significant price cuts on 15 high-cost prescription drugs. This includes well-known medications like Ozempic and Wegovy, aimed at helping manage conditions like Type 2 diabetes and obesity.
These reductions stem from the Medicare drug price negotiation program introduced by the Inflation Reduction Act, which was signed into law by President Biden in 2022. Unlike the previous administration’s approach, which focused on voluntary contracts with drugmakers, this program formally negotiates prices through legislation.
This marks the second wave of negotiations. Last year, Medicare negotiated prices on ten drugs, touching on vital areas like heart disease and diabetes. These changes will begin impacting prices in 2027.
Health and Human Services Secretary Robert F. Kennedy Jr. expressed commitment to lowering healthcare costs: “We will use every tool at our disposal to deliver affordable healthcare to seniors.” However, drugmakers have the option to opt out of negotiations. If they do, they risk losing access to a significant market—Medicare.
The negotiated prices will lower taxpayer spending by an estimated $12 billion, with forecasts suggesting that Medicare beneficiaries could save around $685 million in out-of-pocket costs by 2027.
Here’s a snapshot of some of the biggest price reductions:
- Ozempic, Rybelsus, and Wegovy for diabetes and weight loss: $274 (down from $959).
- Trelegy Ellipta for asthma: $175 (down from $654).
- Xtandi for prostate cancer: $7,004 (down from $13,480).
- Pomalyst, a chemotherapy drug: $8,650 (down from $21,744).
These 15 drugs represent about $42.5 billion in spending, roughly 15% of total Medicare Part D costs in 2024. Dr. Stacie Dusetzina, a health policy expert at Vanderbilt University, commented that these negotiations “should provide some relief for taxpayers and beneficiaries in the long run.” However, she noted that the negotiated price for Ozempic and Wegovy remains higher than previous deals, indicating that there’s still room for improvement.
The issue of drug affordability resonates deeply with the American public. A recent KFF survey revealed that approximately 20% of adults have postponed filling a prescription due to high costs. Moreover, about 14% have altered their medication regimens, such as cutting pills in half to manage expenses.
As the debate continues, many are hopeful that these negotiations will pave the way for more sustainable healthcare costs. The ongoing discussions around prescription drug pricing reflect a broader acknowledgment of the financial strain many Americans face in accessing essential medications. For further details on these changes, you can check the official announcement from the CMS here.
